1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lipocine Inc.
  6. Summary
    LPCN   US53630X1046

LIPOCINE INC.

(LPCN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
0.89(c) 0.891(c) 0.9038(c) 0.9271(c) 0.8844 Last
205 597 160 613 294 870 155 609 90 280 Volume
-3.20% +0.11% +1.44% +2.58% -4.61% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2,21 M - -
Net income 2022 -12,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,47x
Yield 2022 -
Sales 2023 7,49 M - -
Net income 2023 -8,15 M - -
Net Debt 2023 - - -
P/E ratio 2023 -10,7x
Yield 2023 -
Capitalization 82,0 M 82,0 M -
Capi. / Sales 2022 37,2x
Capi. / Sales 2023 11,0x
Nbr of Employees 13
Free-Float 97,5%
More Financials
Company
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. It has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men... 
Sector
Biotechnology & Medical Research
Calendar
06/08 | 12:00pmShareholder meeting
More about the company
Ratings of Lipocine Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about LIPOCINE INC.
05/12Lipocine Says Nonalcoholic Steatohepatitis Treatment Well Tolerated in Open-Label Exten..
MT
05/12LIPOCINE INC. : Financial Statements and Exhibits (form 8-K)
AQ
05/12LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/12Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
PR
05/12Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results
CI
05/09LIPOCINE : Q1 Earnings Snapshot
AQ
05/09LIPOCINE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/09LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/09Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
PR
05/09Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/25Lipocine Inc. Grants Antares Pharma an Exclusive License to Commercialize TLANDO in the..
CI
04/11LIPOCINE : ANNOUNCES BOARD of DIRECTOR APPOINTMENTS - Form 8-K
PU
04/11LIPOCINE INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Finan..
AQ
04/11LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS
PR
04/11Lipocine Inc. Announces Board Appointments
CI
More news
News in other languages on LIPOCINE INC.
05/12Lipocine dit que le traitement de la stéatohépatite non alcoolique est bien toléré dans..
05/12Lipocine Inc. Annonce des résultats positifs de l'étude de prolongation ouverte LPCN 11..
05/09Lipocine Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/25Lipocine Inc. accorde à Antares Pharma une licence exclusive pour la commercialisation ..
04/11Lipocine Inc. annonce des nominations au conseil d'administration
More news
Analyst Recommendations on LIPOCINE INC.
More recommendations
Chart LIPOCINE INC.
Duration : Period :
Lipocine Inc. Technical Analysis Chart | LPCN | US53630X1046 | MarketScreener
Technical analysis trends LIPOCINE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,93 $
Average target price 3,67 $
Spread / Average Target 295%
EPS Revisions
Managers and Directors
Mahesh V. Patel Chairman, President, Chief Executive Officer & CFO
Anthony DelConte Chief Medical Director
Richard Dana Ono Independent Director
Jeffrey Arvin Fink Independent Director
Jill M. Jene Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIPOCINE INC.-6.46%82
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666